Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1

Status

Unknown 4Withdrawn 2Recruiting 2Not yet recruiting 2Completed 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 9Observational 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Breast Neoplasms 13110Neoplasms 10462Carcinoma, Non-Small-Cell Lung 6857Prostatic Neoplasms 6258Colorectal Neoplasms 5925Lung Neoplasms 5091Multiple Myeloma 3568Pancreatic Neoplasms 3552Leukemia, Myeloid, Acute 3503Neoplasm Metastasis 3499Carcinoma, Hepatocellular 3264Ovarian Neoplasms 3160Melanoma 3134Stomach Neoplasms 3051Lymphoma 2981Head and Neck Neoplasms 2595Recurrence 2548Precursor Cell Lymphoblastic Leukemia-Lymphoma 2496Leukemia 2360Colonic Neoplasms 2326Brain Neoplasms 2306Lymphoma, Non-Hodgkin 2265Rectal Neoplasms 2186Uterine Cervical Neoplasms 2182Glioblastoma 2010Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1910Squamous Cell Carcinoma of Head and Neck 1875Lymphoma, Follicular 1847Esophageal Neoplasms 1797

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2Cetuximab 2spartalizumab 1pembrolizumab 1camrelizumab 1Radiosurgery 1Oxaliplatin 1Oncolytic Virotherapy 1KD025 1IFL protocol 1HLX07 1Folfox protocol 1Drug Therapy 1CCT239065 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

11 trials
RecentStart dateEnrollment
CRC × Clear all
NCT03336658 2026-05-05

ITB

Insel Gruppe AG, University Hospital Bern

Completed
150 enrolled

CRC

NCT07283367 2026-05-01

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

Hansoh BioMedical R&D Company

Phase 1/2 Recruiting
502 enrolled

CRC

NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

NCT04984369 2023-08-21

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Shanghai Henlius Biotech

Phase 2 Unknown
50 enrolled

CRC

NCT05314309 2023-01-11

mtFIT

The Netherlands Cancer Institute

Unknown
14,712 enrolled

CRC

NCT05382377 2022-05-19

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Phase EARLY_PHASE1 Unknown
18 enrolled
Other solid neoplasm

CRC

NCT05239650 2022-05-03

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Shanghai Henlius Biotech

Phase 2 Not yet recruiting
50 enrolled

CRC

NCT03337776 2021-08-05

Effect of WhatsApp Messenger on Uptake of CRC Screening Study

Chinese University of Hong Kong

Phase NA Withdrawn

CRC

NCT03601598 2018-07-26

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Harbin Medical University

Phase 1/2 Unknown
41 enrolled
Thoracic

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡